(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 August 2006 (10.08.2006)

PCT

(10) International Publication Number
WO 2006/084058 A3

(51) International Patent Classification:
A61K 31/00 (2006.01)

(21) International Application Number:
PCT/US2006/003717

(22) International Filing Date: 2 February 2006 (02.02.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/649,483	3 February 2005 (03.02.2005)	US
60/671,989	15 April 2005 (15.04.2005)	US

(71) Applicants *(for all designated States except US)*: **THE GENERAL HOSPITAL CORPORATION** [US/US]; 55 Fruit Street, Boston, Massachusetts 02114 (US). **WYETH** [US/US]; Five Giralda Farms, Madison, New Jersey 07940 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HABER, Daniel** [US/US]; 34 Manadnock Road, Chestnut Hill, Massachusetts 02467 (US). **BELL, Daphne Winifred** [US/US]; 7 Arizona Terrece, Apt. 3, Arlington, Massachusetts 02474 (US). **SETTLEMAN, Jeffrey E.** [US/US]; 140 Waverly Avenue, Newton, Massachusetts 02458 (US). **SORDELLA, Raffaella** [IT/US]; 38 Sunset Road, Bedford, Massachusetts 01730 (US). **GODIN-HEYMANN, Nadia G.** [US/US]; 8 Plympton Street, Apt. 47, Cambridge, Massachusetts 02138 (US). **KWAK, Eunice L.** [US/US]; 47 Butler Circle, Marlborough, Massachusetts 01752 (US). **RABINDRAN, Sridhar Krishna** [IN/US]; Two Pamela Drive, Chestnut Ridge, New York 10977 (US).

(74) Agents: **RESNICK, David** et al.; NIXON PEABODY LLP, 100 Summer Street, Boston, Massachusetts 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
14 December 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR TREATING GEFITINIB RESISTANT CANCER

(57) Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/ or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

WO 2006/084058 A3